Effect of Dark chocolate consumption in hypertensive type 2 diabetes

Effect of dark chocolate consumption on ApoB, ApoA-1, lipid profile, hsCRP, glycemic control and blood pressure in type 2 Diabetec patients with hypertention.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812222602N3

Enrollment

Registered

2010-03-13

Start date

2010-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Diabetes mellitus

Interventions

Intervention 1: control: 25 gr of white chocolate for 8 weeks. Intervention 2: intervention: 25 gr of dark chocolate for 8 weeks.

control: 25 gr of white chocolate for 8 weeks

intervention: 25 gr of dark chocolate for 8 weeks

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being volunteer or wishing to attend, 35-65 y old, diagnosed with type 2 diabetes for at least 1 year (FPG = 126 mg/dl or 2hPG = 200 mg/dl), BMI = 40 kg/m2, HbA1C < 9%, Blood pressure = 130/80 mmHg and no regular use of any drugs or supplements with antioxidative (ß-carotene, vitamins C or E) or lipid-lowering properties. Exclusion criteria: Allergy to chocolate, Taking insulin, Smoking cigarette, drinking alcohol or drug abuse, congestive heart failure, malignancies, chronic kidney , hepatic and thyroid diseases , severe cardiac arrhythmias, inflammation following vegetarian or weight-reducing diet 2 months before the study ,Changing medication dosage or physical activity level 2 mo before or during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease Low Density Lipoprotein. Timepoint: 8 weeks. Method of measurement: Laboratory kit.;Decrease blood pressure. Timepoint: 8 week. Method of measurement: sphygmomanometer.;Decrease Apo B. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Increase ApoA-1. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Decrease Triglyceride (TG). Timepoint: 8 weeks. Method of measurement: Laboratory Kit.;Decrease Fasting Blood Sugar (FBS). Timepoint: 8 weeks. Method of measurement: Enzymatic.;Decrease high sensitivity C-reactive protein (hs-CRP). Timepoint: 8 weeks. Method of measurement: Immunoturbidimetry.;Decrease HbA1C. Timepoint: 8 weeks. Method of measurement: Laboratory Kit.	—

Measure

Time frame

Decrease Low Density Lipoprotein. Timepoint: 8 weeks. Method of measurement: Laboratory kit.;Decrease blood pressure. Timepoint: 8 week. Method of measurement: sphygmomanometer.;Decrease Apo B. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Increase ApoA-1. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Decrease Triglyceride (TG). Timepoint: 8 weeks. Method of measurement: Laboratory Kit.;Decrease Fasting Blood Sugar (FBS). Timepoint: 8 weeks. Method of measurement: Enzymatic.;Decrease high sensitivity C-reactive protein (hs-CRP). Timepoint: 8 weeks. Method of measurement: Immunoturbidimetry.;Decrease HbA1C. Timepoint: 8 weeks. Method of measurement: Laboratory Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahriar Eghtesadi

School of Health, Iran University of Medical Sciences

egtesadi@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026